Tortora G, Clair T, Katsaros D, Ally S, Colamonici O, Neckers L M, Tagliaferri P, Jahnsen T, Robins R K, Cho-Chung Y S
Cellular Biochemistry Section, National Cancer Institute, Bethesda, MD 20892.
Proc Natl Acad Sci U S A. 1989 Apr;86(8):2849-52. doi: 10.1073/pnas.86.8.2849.
Two classes (site 1- and site 2-selective) of cAMP analogs, which either alone or in combination demonstrate a preference for binding to type II rather than type I cAMP-dependent protein kinase isozyme, potently inhibit growth in a spectrum of human cancer cell lines in culture. Treatment of K-562 human leukemic cells for 3 days with 30 and 10 microM 8-chloroadenosine 3',5'-cyclic monophosphate (8-Cl-cAMP) (site 1-selective) resulted in 60% and 20% growth inhibition, respectively (with over 90% viability). N6-Benzyl-cAMP (site 2-selective) (30 microM) treatment resulted in 20% growth inhibition by day 3. When 8-Cl-cAMP (10 microM) and N6-benzyl-cAMP (30 microM) were both added, growth was almost completely arrested. The growth inhibition was accompanied by megakaryocytic differentiation in K-562 cells. The untreated control cells expressed little or no detectable levels of glycoprotein IIb-IIIa surface antigen complex. 8-Cl-cAMP (30 microM) treatment for 3 days substantially increased the antigen expression, while N6-benzyl-cAMP caused little or no change in the antigen expression. When cells were treated with 8-Cl-cAMP in combination with N6-benzyl-cAMP, antigen expression was synergistically enhanced, and cells demonstrated megakaryocyte morphology. By Northern blotting, we examined the mRNA levels of the type I and type II protein kinase regulatory subunits (RI alpha and RII beta), the catalytic subunit, and c-myc during 8-Cl-cAMP treatment. The steady-state level of RII beta cAMP receptor mRNA sharply increased within 1 hr of treatment and remained elevated for 3 days, while that of the RI alpha receptor markedly decreased to below control level within 6 hr and remained low during treatment. However, 8-Cl-cAMP did not affect the mRNA level of the catalytic subunit. 8-Cl-cAMP treatment also brought about a rapid decrease in c-myc mRNA. Thus, differential regulation of cAMP receptor genes is an early event in cAMP-induced differentiation and growth control of K-562 leukemia cells.
两类(位点1选择性和位点2选择性)环磷酸腺苷(cAMP)类似物,单独或联合使用时均表现出对II型而非I型cAMP依赖性蛋白激酶同工酶的结合偏好,能有效抑制多种培养的人类癌细胞系的生长。用30 microM和10 microM的8 - 氯腺苷3',5'-环磷酸(8-Cl-cAMP,位点1选择性)处理K - 562人白血病细胞3天,分别导致60%和20%的生长抑制(细胞活力超过90%)。用N6 - 苄基 - cAMP(位点2选择性,30 microM)处理3天时导致20%的生长抑制。当同时添加8-Cl-cAMP(10 microM)和N6 - 苄基 - cAMP(30 microM)时,生长几乎完全停滞。生长抑制伴随着K - 562细胞的巨核细胞分化。未处理的对照细胞表达很少或检测不到糖蛋白IIb - IIIa表面抗原复合物。用30 microM的8-Cl-cAMP处理3天显著增加了抗原表达,而N6 - 苄基 - cAMP对抗原表达几乎没有影响。当细胞用8-Cl-cAMP与N6 - 苄基 - cAMP联合处理时,抗原表达协同增强,细胞呈现巨核细胞形态。通过Northern印迹法,我们检测了8-Cl-cAMP处理期间I型和II型蛋白激酶调节亚基(RIα和RIIβ)、催化亚基和c - myc的mRNA水平。RIIβ cAMP受体mRNA的稳态水平在处理后1小时内急剧增加,并在3天内保持升高,而RIα受体的mRNA水平在6小时内显著降至对照水平以下,并在处理期间保持较低水平。然而,8-Cl-cAMP不影响催化亚基的mRNA水平。8-Cl-cAMP处理还导致c - myc mRNA迅速下降。因此,cAMP受体基因的差异调节是cAMP诱导的K - 562白血病细胞分化和生长控制中的早期事件。